Lilly, Hanmi sign $1.26bn licensing deal for sonefpeglutide

Hanmi inks $1.26b licensing deal with Eli Lilly

Hanmi Pharmaceutical has licensed sonefpeglutide, its GLP-2 drug candidate built on the Lapscovery long-acting platform, to Eli Lilly in a deal worth up to $1.26B ($75M upfront, $1.19B in milestones), with Lilly gaining worldwide rights excluding Korea. The deal signals Lilly's continued expansion into the GLP space beyond GLP-1, confirming long-acting peptide platforms as a high-value M&A and licensing target for pharma majors.